yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
meropenem "fresenius kabi" 1000 mg pulver til injektions-/infusionsvæske, opløsning
fresenius kabi ab - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 1000 mg
meropenem "fresenius kabi" 500 mg pulver til injektions-/infusionsvæske, opløsning
fresenius kabi ab - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 500 mg
piperacillin/tazobactam "fresenius kabi" 2+0,25 g pulver til infusionsvæske, opløsning
fresenius kabi ab - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 2+0,25 g
piperacillin/tazobactam "fresenius kabi" 4+0,5 g pulver til infusionsvæske, opløsning
fresenius kabi ab - piperacillinnatrium, tazobactamnatrium - pulver til infusionsvæske, opløsning - 4+0,5 g